Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells.

Caslini C, Hong S, Ban YJ, Chen XS, Ince TA.

Oncogene. 2019 Sep;38(39):6599-6614. doi: 10.1038/s41388-019-0897-0. Epub 2019 Aug 2.

PMID:
31375747
2.

Ovarian Cancer Treatment Stratification Using Ex Vivo Drug Sensitivity Testing.

Lohse I, Azzam DJ, Al-Ali H, Volmar CH, Brothers SP, Ince TA, Wahlestedt C.

Anticancer Res. 2019 Aug;39(8):4023-4030. doi: 10.21873/anticanres.13558.

PMID:
31366484
3.

Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.

Simpkins F, Jang K, Yoon H, Hew KE, Kim M, Azzam DJ, Sun J, Zhao D, Ince TA, Liu W, Guo W, Wei Z, Zhang G, Mills GB, Slingerland JM.

Clin Cancer Res. 2018 Oct 1;24(19):4874-4886. doi: 10.1158/1078-0432.CCR-17-3697. Epub 2018 Jun 29.

4.

Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma.

Alekseyenko AA, Walsh EM, Zee BM, Pakozdi T, Hsi P, Lemieux ME, Dal Cin P, Ince TA, Kharchenko PV, Kuroda MI, French CA.

Proc Natl Acad Sci U S A. 2017 May 23;114(21):E4184-E4192. doi: 10.1073/pnas.1702086114. Epub 2017 May 8.

5.

VEGFA activates an epigenetic pathway upregulating ovarian cancer-initiating cells.

Jang K, Kim M, Gilbert CA, Simpkins F, Ince TA, Slingerland JM.

EMBO Mol Med. 2017 Mar;9(3):304-318. doi: 10.15252/emmm.201606840.

6.

Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer.

Witt AE, Lee CW, Lee TI, Azzam DJ, Wang B, Caslini C, Petrocca F, Grosso J, Jones M, Cohick EB, Gropper AB, Wahlestedt C, Richardson AL, Shiekhattar R, Young RA, Ince TA.

Oncogene. 2017 Mar 23;36(12):1707-1720. doi: 10.1038/onc.2016.337. Epub 2016 Oct 3.

7.

Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.

Iwanicki MP, Chen HY, Iavarone C, Zervantonakis IK, Muranen T, Novak M, Ince TA, Drapkin R, Brugge JS.

JCI Insight. 2016 Jul 7;1(10). pii: 86829. doi: 10.1172/jci.insight.86829.

8.

Reference-free deconvolution of DNA methylation data and mediation by cell composition effects.

Houseman EA, Kile ML, Christiani DC, Ince TA, Kelsey KT, Marsit CJ.

BMC Bioinformatics. 2016 Jun 29;17:259. doi: 10.1186/s12859-016-1140-4.

9.

Breast cancers from black women exhibit higher numbers of immunosuppressive macrophages with proliferative activity and of crown-like structures associated with lower survival compared to non-black Latinas and Caucasians.

Koru-Sengul T, Santander AM, Miao F, Sanchez LG, Jorda M, Glück S, Ince TA, Nadji M, Chen Z, Penichet ML, Cleary MP, Torroella-Kouri M.

Breast Cancer Res Treat. 2016 Jul;158(1):113-126. doi: 10.1007/s10549-016-3847-3. Epub 2016 Jun 9.

10.

Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.

Thakkar A, Wang B, Picon-Ruiz M, Buchwald P, Ince TA.

Breast Cancer Res Treat. 2016 May;157(1):77-90. doi: 10.1007/s10549-016-3807-y. Epub 2016 Apr 27.

11.

Corrigendum: Chaperone-mediated autophagy degrades mutant p53.

Vakifahmetoglu-Norberg H, Kim M, Xia HG, Iwanicki MP, Ofengeim D, Coloff JL, Pan L, Ince TA, Kroemer G, Brugge JS, Yuan J.

Genes Dev. 2016 Apr 1;30(7):870. doi: 10.1101/gad.280453.116.

12.

Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.

Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, Milikowski C, Bishopric NH, Minn AJ, Creighton CJ, Slingerland JM.

Breast Cancer Res Treat. 2016 Apr;156(2):405-6. doi: 10.1007/s10549-016-3752-9.

13.

Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b-Mediated Malignant Progression.

Picon-Ruiz M, Pan C, Drews-Elger K, Jang K, Besser AH, Zhao D, Morata-Tarifa C, Kim M, Ince TA, Azzam DJ, Wander SA, Wang B, Ergonul B, Datar RH, Cote RJ, Howard GA, El-Ashry D, Torné-Poyatos P, Marchal JA, Slingerland JM.

Cancer Res. 2016 Jan 15;76(2):491-504. doi: 10.1158/0008-5472.CAN-15-0927. Epub 2016 Jan 7.

14.

MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.

Hew KE, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, Gu M, Wei Z, Zhang G, Brafford P, Gao W, Lu Y, Mills GB, Slingerland JM, Simpkins F.

Clin Cancer Res. 2016 Feb 15;22(4):935-47. doi: 10.1158/1078-0432.CCR-15-0534. Epub 2015 Oct 19.

15.

Of mice and women: a comparative tissue biology perspective of breast stem cells and differentiation.

Dontu G, Ince TA.

J Mammary Gland Biol Neoplasia. 2015 Jun;20(1-2):51-62. doi: 10.1007/s10911-015-9341-4. Epub 2015 Aug 19. Review.

16.

Heat shock factor 1 induces cancer stem cell phenotype in breast cancer cell lines.

Wang B, Lee CW, Witt A, Thakkar A, Ince TA.

Breast Cancer Res Treat. 2015 Aug;153(1):57-66. doi: 10.1007/s10549-015-3521-1. Epub 2015 Jul 30.

17.

Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours.

Ince TA, Sousa AD, Jones MA, Harrell JC, Agoston ES, Krohn M, Selfors LM, Liu W, Chen K, Yong M, Buchwald P, Wang B, Hale KS, Cohick E, Sergent P, Witt A, Kozhekbaeva Z, Gao S, Agoston AT, Merritt MA, Foster R, Rueda BR, Crum CP, Brugge JS, Mills GB.

Nat Commun. 2015 Jun 17;6:7419. doi: 10.1038/ncomms8419.

18.

Normal cell-type epigenetics and breast cancer classification: a case study of cell mixture-adjusted analysis of DNA methylation data from tumors.

Houseman EA, Ince TA.

Cancer Inform. 2014 Dec 9;13(Suppl 4):53-64. doi: 10.4137/CIN.S13980. eCollection 2014.

19.

Normal cell phenotypes of breast epithelial cells provide the foundation of a breast cancer taxonomy.

Santagata S, Ince TA.

Expert Rev Anticancer Ther. 2014 Dec;14(12):1385-9. doi: 10.1586/14737140.2014.956096. Epub 2014 Sep 27.

20.

Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance.

Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS.

J Clin Invest. 2014 Jun;124(6):2611-25. doi: 10.1172/JCI69815. Epub 2014 Apr 24.

21.

Taxonomy of breast cancer based on normal cell phenotype predicts outcome.

Santagata S, Thakkar A, Ergonul A, Wang B, Woo T, Hu R, Harrell JC, McNamara G, Schwede M, Culhane AC, Kindelberger D, Rodig S, Richardson A, Schnitt SJ, Tamimi RM, Ince TA.

J Clin Invest. 2014 Feb;124(2):859-70. doi: 10.1172/JCI70941. Epub 2014 Jan 27.

22.

Rb suppresses collective invasion, circulation and metastasis of breast cancer cells in CD44-dependent manner.

Kim KJ, Godarova A, Seedle K, Kim MH, Ince TA, Wells SI, Driscoll JJ, Godar S.

PLoS One. 2013 Dec 4;8(12):e80590. doi: 10.1371/journal.pone.0080590. eCollection 2013.

23.

Gene expression signature of normal cell-of-origin predicts ovarian tumor outcomes.

Merritt MA, Bentink S, Schwede M, Iwanicki MP, Quackenbush J, Woo T, Agoston ES, Reinhardt F, Crum CP, Berkowitz RS, Mok SC, Witt AE, Jones MA, Wang B, Ince TA.

PLoS One. 2013 Nov 26;8(11):e80314. doi: 10.1371/journal.pone.0080314. eCollection 2013.

24.

A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells.

Petrocca F, Altschuler G, Tan SM, Mendillo ML, Yan H, Jerry DJ, Kung AL, Hide W, Ince TA, Lieberman J.

Cancer Cell. 2013 Aug 12;24(2):182-96. doi: 10.1016/j.ccr.2013.07.008.

25.

Chaperone-mediated autophagy degrades mutant p53.

Vakifahmetoglu-Norberg H, Kim M, Xia HG, Iwanicki MP, Ofengeim D, Coloff JL, Pan L, Ince TA, Kroemer G, Brugge JS, Yuan J.

Genes Dev. 2013 Aug 1;27(15):1718-30. doi: 10.1101/gad.220897.113. Erratum in: Genes Dev. 2013 Sep 1;27(17):1947. Genes Dev. 2016 Apr 1;30(7):870.

26.

PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.

Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, Milikowski C, Bishopric NH, Minn AJ, Creighton CJ, Slingerland JM.

Breast Cancer Res Treat. 2013 Apr;138(2):369-81. doi: 10.1007/s10549-012-2389-6. Epub 2013 Feb 21. Erratum in: Breast Cancer Res Treat. 2016 Apr;156(2):405-6.

27.

Induced pluripotent stem cells with a mitochondrial DNA deletion.

Cherry AB, Gagne KE, McLoughlin EM, Baccei A, Gorman B, Hartung O, Miller JD, Zhang J, Zon RL, Ince TA, Neufeld EJ, Lerou PH, Fleming MD, Daley GQ, Agarwal S.

Stem Cells. 2013 Jul;31(7):1287-97. doi: 10.1002/stem.1354.

28.

Defined, serum-free conditions for in vitro culture of primary human T-ALL blasts.

Yost AJ, Shevchuk OO, Gooch R, Gusscott S, You MJ, Ince TA, Aster JC, Weng AP.

Leukemia. 2013 Jun;27(6):1437-40. doi: 10.1038/leu.2012.337. Epub 2012 Nov 21. No abstract available.

29.

Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.

Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, Pedram A, Levin ER, Reis IM, Rabinovich B, Azzam D, Xu XX, Ince TA, Yang JY, Verhaak RG, Lu Y, Mills GB, Slingerland JM.

Clin Cancer Res. 2012 Nov 1;18(21):5911-23. doi: 10.1158/1078-0432.CCR-12-1257. Epub 2012 Aug 15.

30.

HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers.

Mendillo ML, Santagata S, Koeva M, Bell GW, Hu R, Tamimi RM, Fraenkel E, Ince TA, Whitesell L, Lindquist S.

Cell. 2012 Aug 3;150(3):549-62. doi: 10.1016/j.cell.2012.06.031.

31.

Ovarian cancer spheroids use myosin-generated force to clear the mesothelium.

Iwanicki MP, Davidowitz RA, Ng MR, Besser A, Muranen T, Merritt M, Danuser G, Ince TA, Brugge JS.

Cancer Discov. 2011 Jul;1(2):144-57. doi: 10.1158/2159-8274.CD-11-0010. Erratum in: Cancer Discov. 2011 Dec;1(7):626. Ince, Tan [corrected to Ince, Tan A].

32.

High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer.

Santagata S, Hu R, Lin NU, Mendillo ML, Collins LC, Hankinson SE, Schnitt SJ, Whitesell L, Tamimi RM, Lindquist S, Ince TA.

Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18378-83. doi: 10.1073/pnas.1115031108. Epub 2011 Oct 31.

33.

Differentiation of NUT midline carcinoma by epigenomic reprogramming.

Schwartz BE, Hofer MD, Lemieux ME, Bauer DE, Cameron MJ, West NH, Agoston ES, Reynoird N, Khochbin S, Ince TA, Christie A, Janeway KA, Vargas SO, Perez-Atayde AR, Aster JC, Sallan SE, Kung AL, Bradner JE, French CA.

Cancer Res. 2011 Apr 1;71(7):2686-96. doi: 10.1158/0008-5472.CAN-10-3513. Epub 2011 Mar 29.

34.

Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective.

Jarboe EA, Folkins AK, Drapkin R, Ince TA, Agoston ES, Crum CP.

Histopathology. 2009 Nov;55(5):619. doi: 10.1111/j.1365-2559.2009.03408.x. No abstract available.

PMID:
19912369
35.

Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells.

Chan EM, Ratanasirintrawoot S, Park IH, Manos PD, Loh YH, Huo H, Miller JD, Hartung O, Rho J, Ince TA, Daley GQ, Schlaeger TM.

Nat Biotechnol. 2009 Nov;27(11):1033-7. doi: 10.1038/nbt.1580. Epub 2009 Oct 11.

PMID:
19826408
36.

Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells.

Elmasri H, Karaaslan C, Teper Y, Ghelfi E, Weng M, Ince TA, Kozakewich H, Bischoff J, Cataltepe S.

FASEB J. 2009 Nov;23(11):3865-73. doi: 10.1096/fj.09-134882. Epub 2009 Jul 22.

37.

Squamous morules are functionally inert elements of premalignant endometrial neoplasia.

Lin MC, Lomo L, Baak JP, Eng C, Ince TA, Crum CP, Mutter GL.

Mod Pathol. 2009 Feb;22(2):167-74. doi: 10.1038/modpathol.2008.146. Epub 2008 Sep 19.

38.

Do-it-yourself (DIY) pathology.

Ince TA, Ward JM, Valli VE, Sgroi D, Nikitin AY, Loda M, Griffey SM, Crum CP, Crawford JM, Bronson RT, Cardiff RD.

Nat Biotechnol. 2008 Sep;26(9):978-9; discussion 979. doi: 10.1038/nbt0908-978. No abstract available.

PMID:
18779800
39.

Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression.

Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J, Liu A, Miu K, Watnick RS, Reinhardt F, McAllister SS, Jacks T, Weinberg RA.

Cell. 2008 Jul 11;134(1):62-73. doi: 10.1016/j.cell.2008.06.006.

40.

Systemic endocrine instigation of indolent tumor growth requires osteopontin.

McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saelzler MP, Ince TA, Reinhardt F, Harris LN, Hylander BL, Repasky EA, Weinberg RA.

Cell. 2008 Jun 13;133(6):994-1005. doi: 10.1016/j.cell.2008.04.045.

41.

Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective.

Jarboe EA, Folkins AK, Drapkin R, Ince TA, Agoston ES, Crum CP.

Histopathology. 2008 Aug;53(2):127-38. doi: 10.1111/j.1365-2559.2007.02938.x. Epub 2008 Feb 22. Review.

PMID:
18298580
42.

Human embryonic stem cell derivation from poor-quality embryos.

Lerou PH, Yabuuchi A, Huo H, Takeuchi A, Shea J, Cimini T, Ince TA, Ginsburg E, Racowsky C, Daley GQ.

Nat Biotechnol. 2008 Feb;26(2):212-4. doi: 10.1038/nbt1378. Epub 2008 Jan 27.

PMID:
18223642
43.

Reprogramming of human somatic cells to pluripotency with defined factors.

Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ.

Nature. 2008 Jan 10;451(7175):141-6. Epub 2007 Dec 23.

PMID:
18157115
44.

The terminology of teratocarcinomas and teratomas.

Lensch MW, Ince TA.

Nat Biotechnol. 2007 Nov;25(11):1211; author reply 1211-2. No abstract available.

PMID:
17989663
45.

Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes.

Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE, Iglehart JD, Weinberg RA.

Cancer Cell. 2007 Aug;12(2):160-70.

46.

From whence will they come? - A perspective on the acute shortage of pathologists in biomedical research.

Barthold SW, Borowsky AD, Brayton C, Bronson R, Cardiff RD, Griffey SM, Ince TA, Nikitin AY, Sundberg J, Valli VE, Ward JM.

J Vet Diagn Invest. 2007 Jul;19(4):455-6. No abstract available.

PMID:
17609364
47.

The distal fallopian tube: a new model for pelvic serous carcinogenesis.

Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y.

Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9. Review.

PMID:
17218844
48.

Microglandular hyperplasia: a model for the de novo emergence and evolution of endocervical reserve cells.

Witkiewicz AK, Hecht JL, Cviko A, McKeon FD, Ince TA, Crum CP.

Hum Pathol. 2005 Feb;36(2):154-61.

PMID:
15754292
49.

Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer.

Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T.

Nat Med. 2005 Jan;11(1):63-70. Epub 2004 Dec 26.

PMID:
15619626
50.

Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis.

Hecht JL, Ince TA, Baak JP, Baker HE, Ogden MW, Mutter GL.

Mod Pathol. 2005 Mar;18(3):324-30.

Supplemental Content

Support Center